Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Taiwan Semiconductor Mfg. Co. Ltd. (TSM) Price & Performance

Heron Therapeutics IncTrade
Taiwan Semiconductor Mfg. Co. Ltd.Trade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Taiwan Semiconductor Mfg. Co. Ltd. — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while Taiwan Semiconductor Mfg. Co. Ltd. trades at $423.49 (market cap $1.88T). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 20555.4× Heron Therapeutics Inc's market cap, and Taiwan Semiconductor Mfg. Co. Ltd. pays a 0.94% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HRTXTSM
Market Cap
$91.46M$1.88T
Sector
HealthTechnology
52-Week High
$1.96$477.57
52-Week Low
$0.39$227.33
Enterprise Value
$189.36M$1.81T
Dividend Yield
0.94%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.

Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.

Taiwan Semiconductor Mfg. Co. Ltd.

TSM is trading at $401.43, up 0.77% today, amid a bearish technical signal but strong fundamental performance. The company reported robust Q2 2026 earnings, beating estimates with 33.7% revenue growth, and announced a $100 billion expansion in Arizona to capitalize on AI chip demand. Valuation ratios like a P/E of 29.81 and P/S of 14.88 reflect premium pricing, while profitability remains high with a net margin of 49.92%.

The outlook is positive due to sustained AI-driven demand and strategic investments, but risks include sector volatility and execution challenges in expansion. Analyst consensus is strongly bullish with a $547.50 price target, suggesting significant upside potential from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Taiwan Semiconductor Mfg. Co. Ltd.

Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.

Read more on TSM